Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to INVEGA SUSTENNA®
Belmore Neidrauer successfully represented Janssen in the Federal Court of Appeal on another appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia. The Court of Appeal rejected Pharmascience’s appeal of the finding of inducement. In doing so, the Court of Appeal clarified the doctrine of implied licence and found that the doctrine did not apply.
Link to the case: Pharmascience v. Janssen
